AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

Study Evaluating the Pharmacokinetic and Mass Balance of Single Dose [14C] AZD5718 in Volunteers

Phase 1

Completed

Conditions: Cardiovascular Disease

Interventions: Drug: [14C]AZD5718 Oral Suspension

First Posted Date: 2019-05-14

Last Posted Date: 2019-07-15

Lead Sponsor: AstraZeneca

Target Recruit Count: 6

Registration Number: NCT03948451

Locations: 🇬🇧
Research Site, Ruddington, United Kingdom

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Phase 2

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Durvalumab
Drug: Osimertinib
Drug: Necitumumab
Drug: Carboplatin
Drug: Alectinib
Drug: Selumetinib
Drug: Datopotamab deruxtecan
Drug: Savolitinib
Drug: Gefitinib
Drug: Selpercatinib
Drug: Pemetrexed
Drug: Etoposide
Drug: Cisplatin

First Posted Date: 2019-05-10

Last Posted Date: 2025-01-30

Lead Sponsor: AstraZeneca

Target Recruit Count: 247

Registration Number: NCT03944772

Locations: 🇸🇪
Research Site, Stockholm, Sweden

A Study to Compare the Pharmacokinetics of Budesonide Delivered by PT027 Compared With Pulmicort Flexhaler (ELBRUS)

Phase 1

Completed

Conditions: Relative Bioavailability

Interventions: Drug: BDA MDI 160/180 mcg
Drug: Pulmicort Flexhaler 180 mcg

First Posted Date: 2019-05-01

Last Posted Date: 2019-10-01

Lead Sponsor: AstraZeneca

Target Recruit Count: 11

Registration Number: NCT03934333

Locations: 🇺🇸
Research Site, Baltimore, Maryland, United States

Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies

Phase 1

Active, not recruiting

Conditions: Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma
Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia
Phase I: Relapsed or Refractory B-cell Malignancies

Interventions: Drug: Acalabrutinib

First Posted Date: 2019-04-30

Last Posted Date: 2025-03-20

Lead Sponsor: AstraZeneca

Target Recruit Count: 105

Registration Number: NCT03932331

Locations: 🇨🇳
Research Site, Zhengzhou, China

Prevalence of the Eosinophilic Phenotype Among Severe Asthma Patients

Completed

Conditions: Severe Asthma

First Posted Date: 2019-04-30

Last Posted Date: 2021-01-29

Lead Sponsor: AstraZeneca

Target Recruit Count: 794

Registration Number: NCT03931954

Locations: 🇸🇦
Research Site, Riyadh, Saudi Arabia

Pharmacokinetic Study of Benralizumab in Healthy Chinese Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Biological: Benralizumab

First Posted Date: 2019-04-26

Last Posted Date: 2019-08-30

Lead Sponsor: AstraZeneca

Target Recruit Count: 36

Registration Number: NCT03928262

Locations: 🇭🇰
Research Site, Hong Kong, Hong Kong

Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma

Phase 3

Completed

Conditions: Asthma

Interventions: Other: Placebo

First Posted Date: 2019-04-25

Last Posted Date: 2024-08-26

Lead Sponsor: AstraZeneca

Target Recruit Count: 405

Registration Number: NCT03927157

Locations: 🇵🇭
Research Site, Quezon City, Philippines

BRazilian Asthmatics Patients EOSinophilic Profile (BRAEOS)

Completed

Conditions: Severe Asthma

First Posted Date: 2019-04-24

Last Posted Date: 2020-08-14

Lead Sponsor: AstraZeneca

Target Recruit Count: 414

Registration Number: NCT03925415

Locations: 🇧🇷
Research Site, Sorocaba, Brazil

An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients

Phase 4

Completed

Conditions: Airway Inflammation
Asthma

Interventions: Combination Product: SYMBICORT and salbutamol

First Posted Date: 2019-04-23

Last Posted Date: 2025-01-22

Lead Sponsor: AstraZeneca

Target Recruit Count: 42

Registration Number: NCT03924635

Locations: 🇬🇧
Research Site, Wishaw, United Kingdom

Study to Assess Effect of Device and Formulation on Pharmacokinetics (PK) of AZD1402

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: AZD1402

First Posted Date: 2019-04-19

Last Posted Date: 2019-06-21

Lead Sponsor: AstraZeneca

Target Recruit Count: 18

Registration Number: NCT03921268

Locations: 🇬🇧
Research Site, Harrow, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy